VERU INC. Increase (Decrease) in Accrued Liabilities
VERU INC. (VERU) reported Increase (Decrease) in Accrued Liabilities of $2.23 million for the 6-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2024-05-08
- VERU INC. increase (decrease) in accrued liabilities for the quarter ending 2024-03-31 was $937.76K.
- VERU INC. increase (decrease) in accrued liabilities for the quarter ending 2023-12-31 was $1.30M, a 84.52% decline year-over-year.
- VERU INC. increase (decrease) in accrued liabilities for the quarter ending 2023-09-30 was -$5.01M.
- VERU INC. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was -$5.80M, a 173.56% decline year-over-year.
- VERU INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$11.72M, a 242.98% decline from fiscal 2022.
- VERU INC. increase (decrease) in accrued liabilities for fiscal 2022 was $8.20M, a 92.91% increase from fiscal 2021.
- VERU INC. increase (decrease) in accrued liabilities for fiscal 2021 was $4.25M.
- VERU INC. increase (decrease) in accrued liabilities for fiscal 2020 was -$946.39K, a 147.24% decline from fiscal 2019.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $937.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | $2.23M 10-Q · filed 2024-05-08 | -$2.78M derived: sum of 3 quarters · filed 2024-05-08 | -$8.57M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2023-12-31 | $1.30M 10-Q · filed 2024-04-01 | -$3.71M derived: sum of 2 quarters · filed 2024-04-01 | -$9.51M derived: sum of 3 quarters · filed 2024-04-01 | -$18.79M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2023-09-30 | -$5.01M derived: 10-K/A 12 month − 10-K/A 9 month · filed 2024-04-01 | -$10.81M derived: sum of 2 quarters · filed 2024-04-01 | -$20.09M derived: sum of 3 quarters · filed 2024-05-08 | -$11.72M 10-K/A · filed 2024-04-01 | -$13.62M 10-K · filed 2023-12-08 | |||
| 2023-06-30 | -$5.80M derived: 10-K/A 9 month − 10-Q 6 month · filed 2024-04-01 | -$15.07M derived: sum of 2 quarters · filed 2024-05-08 | -$6.71M 10-K/A · filed 2024-04-01 | -$10.36M 10-Q · filed 2023-08-10 | -$6.77M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2023-03-31 | -$9.28M derived: 10-Q 6 month − 10-K/A 3 month · filed 2024-05-08 | -$911.57K 10-Q · filed 2024-05-08 | $1.37M 10-Q · filed 2023-05-11 | -$974.33K derived: sum of 3 quarters · filed 2024-05-08 | $6.91M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $8.37M 10-K/A · filed 2024-04-01 | $8.24M 10-Q · filed 2023-02-09 | $8.30M derived: sum of 2 quarters · filed 2024-04-01 | $16.18M derived: sum of 3 quarters · filed 2024-04-01 | $19.39M derived: sum of 4 quarters · filed 2024-04-01 | |||
| 2022-09-30 | -$62.75K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $7.82M derived: sum of 2 quarters · filed 2024-04-01 | $11.03M derived: sum of 3 quarters · filed 2024-04-01 | $8.20M 10-K/A · filed 2024-04-01 | $8.70M 10-K · filed 2022-12-05 | |||
| 2022-06-30 | $7.88M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | $11.09M derived: sum of 2 quarters · filed 2023-11-15 | $8.26M 10-Q/A · filed 2023-11-15 | $9.72M derived: sum of 4 quarters · filed 2023-11-15 | ||||
| 2022-03-31 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-11 | $378.57K 10-Q · filed 2023-05-11 | $1.84M derived: sum of 3 quarters · filed 2023-05-11 | $4.44M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$2.83M 10-Q · filed 2023-02-09 | -$1.37M derived: sum of 2 quarters · filed 2023-02-09 | $1.23M derived: sum of 3 quarters · filed 2023-02-09 | $970.02K derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-09-30 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $4.06M derived: sum of 2 quarters · filed 2022-12-05 | $3.80M derived: sum of 3 quarters · filed 2022-12-05 | $4.25M 10-K · filed 2022-12-05 | ||||
| 2021-06-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $2.34M derived: sum of 2 quarters · filed 2022-08-11 | $2.78M 10-Q · filed 2022-08-11 | $1.28M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$255.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12 | $191.73K 10-Q · filed 2022-05-12 | -$1.31M derived: sum of 3 quarters · filed 2022-05-12 | -$461.23K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $447.10K 10-Q · filed 2022-02-09 | -$1.06M derived: sum of 2 quarters · filed 2022-02-09 | -$205.86K derived: sum of 3 quarters · filed 2022-02-09 | -$253.89K derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-09-30 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | -$652.96K derived: sum of 2 quarters · filed 2021-12-02 | -$700.99K derived: sum of 3 quarters · filed 2021-12-02 | -$946.39K 10-K · filed 2021-12-02 | ||||
| 2020-06-30 | $849.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $801.73K derived: sum of 2 quarters · filed 2021-08-12 | $556.33K 10-Q · filed 2021-08-12 | $1.99M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | -$48.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | -$293.43K 10-Q · filed 2021-05-12 | $1.14M derived: sum of 3 quarters · filed 2021-05-12 | $2.10M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | -$245.40K 10-Q · filed 2021-02-10 | $1.19M derived: sum of 2 quarters · filed 2021-02-10 | $2.15M derived: sum of 3 quarters · filed 2021-02-10 | $2.41M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-09-30 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $2.39M derived: sum of 2 quarters · filed 2020-12-10 | $2.66M derived: sum of 3 quarters · filed 2020-12-10 | $2.00M 10-K · filed 2020-12-10 | $2.19M 10-K · filed 2019-12-12 | |||
| 2019-06-30 | $957.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-13 | $1.22M derived: sum of 2 quarters · filed 2020-08-13 | $566.56K 10-Q · filed 2020-08-13 | $1.46M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $264.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | -$391.01K 10-Q · filed 2020-05-13 | $501.12K derived: sum of 3 quarters · filed 2020-05-13 | $579.48K derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | -$655.48K 10-Q · filed 2020-02-12 | $236.65K derived: sum of 2 quarters · filed 2020-02-12 | $315.01K derived: sum of 3 quarters · filed 2020-02-12 | |||||
| 2018-09-30 | $892.13K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $970.49K derived: sum of 2 quarters · filed 2019-12-12 | $1.35M 10-K · filed 2019-12-12 | |||||
| 2018-06-30 | $78.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-08 | $454.32K 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $375.96K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |